XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

The main objective of this study is to observe and evaluate the safety and tolerability of the XP-005 personalized tumor mRNA vaccine, either alone or in combination with toripalimab, for the treatment of acute myeloid leukemia patients who are in remission with minimal residual disease (MRD) positive but cannot undergo allogeneic hematopoietic stem cell transplantation.

NCT Number	NCT06980155
Lead Sponsor	Shanghai Jiao Tong University School of Medicine Collaborators: Shanghai Xinpu BioTechnology Company Limited
Conditions	Acute Myeloid Leukemia
Enrollment	60 participants
Start Date	2025-05-30
Primary Completion	2027-01-30 (estimated)
Study Completion	2028-08-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-20